



RA Models of Care Toolkit

Medical management

Treatment options (Box 8)

1) JointHealth™ Medications Guide

<https://jointhealth.org/pdfs/MedicationsGuideJune2017.pdf>

2) Arthritis Consumer Experts: JointHealth™ Education online course: JHEd:Advanced Therapies

<http://info.jointhealth.org/jhed-landing-page>

3) Arthritis Consumer Experts: Biosim•Exchange

<https://biosim.jointhealth.org>

4) Arthritis Consumer Experts: Biosimilars Education Videos

<http://info.jointhealth.org/resources>

5) EULAR: Recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

<https://ard.bmj.com/content/76/6/960>

6) ACR: 2012 Update of the 2008 American College of Rheumatology (ACR) Recommendations for the use of Disease-Modifying Anti-Rheumatic Drugs and Biologics in the treatment of Rheumatoid Arthritis (RA)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081542/>

RA Models of Care Toolkit

Medical management

7) EULAR: “Low-dose glucocorticoids are safe to use in early rheumatoid arthritis”

<https://promotions.bmj.com/ardsummaries/2017/11/21/low-dose-glucocorticoids-are-safe-to-use-in-early-rheumatoid-arthritis/#more-698>

8) EULAR: “[Managing the use of glucocorticoid therapy in rheumatic disease](https://promotions.bmj.com/ardsummaries/2016/08/18/managing-the-use-of-glucocorticoid-therapy-in-rheumatic-disease/)”

<https://promotions.bmj.com/ardsummaries/2016/08/18/managing-the-use-of-glucocorticoid-therapy-in-rheumatic-disease/>

9) EULAR: “Biologics should be compared to the highest possible dose of methotrexate”

<https://promotions.bmj.com/ardsummaries/2016/09/06/biologics-should-be-compared-to-the-highest-possible-dose-of-methotrexate/>

10) EULAR: “Newly updated advice on using DMARDs for RA”

<https://promotions.bmj.com/ardsummaries/2014/04/25/newly-updated-advice-on-using-dmards-for-ra/#more-23>

11) EULAR: “Recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis”

<https://ard.bmj.com/content/72/6/804>

12) European Medicines Agency: “Biosimilars Medicines”

<https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines-overview>



RA Models of Care Toolkit

Medical management

13) European Medicines Agency and European Commission: “Biosimilars medicines animated video for patients”

<https://www.youtube.com/playlist?list=PL7K5dNgKnawb3lQri7llr5wbaWxP71jQJ>

14) European Commission: “Biosimilars information guide for patients”

<http://ec.europa.eu/docsroom/documents/26643>

15) “Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region”

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508389/>

16) “Inequities in access to biologic and synthetic DMARDs across 46 European countries”

<https://ard.bmj.com/content/73/1/198>